电影《1993》米莉亚姆,三年中国中文高清免费观看,巨茎插入李淑芬体内视频

GSK2838232

NMR下載 COA and HPLC MSDS下載
names：
GSK2838232
CAS號：
1443460-91-0
MDL Number： No data available
MF(分子式)： C48H73ClN2O6 MW(分子量)： 809.56
EINECS:No data available Reaxys Number:No data available
Pubchem ID:71580991 Brand:BIOFOUNT

GSK2838232(1443460-91-0)是抗艾滋病毒劑，用于治療艾滋病和/或制止艾滋病毒感染傳播的藥物。這些不包括用于治療與艾滋病相關的癥狀或機會性感染的藥物.通過高含量成像確定抗病毒活性是在10 uM時抑制SARS-CoV-2誘導的Caco-2細胞的細胞毒性，作用時間為10 uM。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000654-10mg	10mg	99.26%	￥ 5062.00	￥ 5062.00		2-3天	- +	￥ 0.00
YZM000654-5mg	5mg	99.26%	￥ 3412.50	￥ 3412.50		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	GSK2838232(1443460-91-0),GSK-2838232;GSK2838232;GSK 2838232;4-[[（（3aR，5aR，5bR，7aR，9S，11aR，11bR，13aS）-3a-[（1R）-2-[（4-氯苯基）甲基-[2-（二甲基氨基）乙基]氨基]- 1-羥乙基] -5a，5b，8,8,11a-五甲基-2-氧代-1-丙-2-基-4,5,6,7,7a，9,10,11,11b，12,13 ，13a-十二烷基-3H-環戊[a] chrysen-9-基]氧基] -2,2-dime;
英文別名	GSK2838232(1443460-91-0),4-[[(3aR,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-[(1R)-2-[(4-chlorophenyl)methyl-[2-(dimethylamino)ethyl]amino]-1-hydroxyethyl]-5a,5b,8,8,11a-pentamethyl-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3H-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dime;
CAS號	1443460-91-0
Inchi	InChI = 1S / C48H73ClN2O6 / c1-30（2）40-34（52）26-48（37（53）29-51（25-24-50（10）11）28-31-12-14-32（ 49）15-13-31）23-22-46（8）33（41（40）48）16-17-36-45（7）20-19-38（57-39（54）27-43（ 3,4）42（55）56）44（5,6）35（45）18-21-47（36,46）9 / h12-15,30,33,35-38,53H，16-29H2， 1-11H3，（H，55,56）/ t33-，35 +，36-，37 +，38 +，45 +，46-，47-，48 + / m1 / s1
InchiKey	MEOWKUXNVNJAMY-PZFKGGKESA-N
分子式 Formula	C48H73ClN2O6
分子量 Molecular Weight	809.56
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 50 mg/mL(61.76 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	白色至灰白色固體粉末,Power
儲藏條件 Storage conditions	存放在陰涼干燥處，短期（數天至數周）在0-4℃，長期（數月至數年）在-56℃。保質期2年。

GSK2838232(1443460-91-0)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:GSK2838232試劑,GSK2838232雜質,GSK2838232中間體,GSK2838232密度,GSK2838232合成,GSK2838232密度,GSK2838232溶解度,GSK2838232旋光度,GSK2838232閃點,GSK2838232購買,

產品說明	(1443460-91-0)GSK2838232 GSK2838232是Betulin的衍生物,是一種新型的人類免疫病毒(HIV)成熟抑制劑,正在開發用于治療慢性HIV感染.
Introduction	GSK2838232(1443460-91-0)inhibit HIV reverse transcriptase activity across a broad panel of HIV isolates, extracted from patent WO/2013090664A1, compound51.
Application1
Application2
Application3

GSK2838232(1443460-91-0)藥理學：
GSK2838232(1443460-91-0)是Betulin的衍生物，GSK2838232是一種新型的人類免疫病毒（HIV）成熟抑制劑，正在開發用于治療慢性HIV感染。GSK2838232是抗艾滋病毒劑，用于治療艾滋病和/或制止艾滋病毒感染傳播的藥物。這些不包括用于治療與艾滋病相關的癥狀或機會性感染的藥物.通過高含量成像確定抗病毒活性是在10 uM時抑制SARS-CoV-2誘導的Caco-2細胞的細胞毒性，作用時間為10 uM。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Hatcher Mark Andrew, et al. Preparation of betulin derivatives for the treatment of HIV. From PCT Int. Appl. (2013), WO 2013090664 A1 20130620.

GSK2838232(1443460-91-0)參考文獻：

1、US2018042944 藥物成分 2017-10-19
This web page summarizes information in PubChem about patent US-2018042944-A1. This includes chemicals mentioned, as reported , as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed, please visit the PubChem patents help page. The present Invention relates to long acting pharmaceutical compositions of betulin derivatives or pharmaceutically acceptable salts thereof, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.

2、US2017348324 樺木的衍生物 2017-08-24
This web page summarizes information in PubChem about patent US-2017348324-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed,
The present invention relates to compounds characterized by having a structure according to the following Formula I: n n n n n n n n n n , or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

3、US2017252356 用木犀草素衍生物治療HIV的化合物和組合物 2017-03-21
This web page summarizes information in PubChem about patent US-2017252356-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed。
The present invention relates to compounds characterized by having a structure according to the following Formula I: n n n n n n n n n n or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

4、US2016120878 樺木的衍生物 2015-12-23 2016-05-05
This web page summarizes information in PubChem about patent US-2016120878-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed,
The present invention relates to compounds characterized by having a structure according to the following formula I: n n n n n n n n n n n n or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

5、US2014357643 樺木素衍生物 2014-08-18 2014-12-04
This web page summarizes information in PubChem about patent US-2014357643-A1. This includes chemicals mentioned, as reported by PubChem contributors, as well as other content, such as title, abstract, and International Patent Classification (IPC) codes. To read more about how this page was constructed,
The present invention relates to compounds characterized by having a structure according to the following Formula I: n n n n n n n n n n , or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開